Online citations, reference lists, and bibliographies.
← Back to Search

Phase 2 Study Of Sorafenib In Malignant Mesothelioma Previously Treated With Platinum-Containing Chemotherapy

S. Papa, S. Popat, R. Shah, A. Prevost, R. Lal, B. McLennan, P. Cane, L. Lang-Lazdunski, Z. Viney, J. Dunn, S. Barrington, D. Landau, J. Spicer
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: The incidence of mesothelioma is rising. First-line cisplatin and pemetrexed confers a survival benefit, with a median progression-free survival (PFS) of 5.7 months. Sorafenib inhibits tyrosine kinases, including receptors for vascular endothelial growth factor, which are implicated in mesothelioma pathogenesis by preclinical and clinical data. Methods: Sorafenib, at 400 mg twice daily, was assessed in a single-arm multicenter phase 2 study, using Simon’s two-stage design. Eligible patients had received platinum combination chemotherapy earlier. The primary endpoint was PFS at 6 months, with secondary endpoints, including response rate and metabolic response, assessed using fluorodeoxyglucose positron emission tomography. Published reference values for PFS in mesothelioma provide a benchmark for the null hypothesis of 28% progression-free at 6 months, and for moderate or significant clinical activity of 35% or 43% progression-free at 6 months, respectively. Results: Fifty-three patients (72%) were treated. Most had epithelioid histology. Ninety-three percent of patients had a performance status 0 or 1. Treatment was well tolerated with few grade 3 or 4 toxicities. Median PFS was 5.1 months, with 36% of patients being progression-free at 6 months. Nine percent of patients remained on study beyond 1 year. Changes in fluorodeoxyglucose positron emission tomography parameters did not predict clinical outcome. Conclusions: Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy. PFS of sorafenib compares favorably with that reported for other targeted agents, and suggests moderate activity in this disease.
This paper references
10.1016/0197-2456(89)90015-9
Optimal two-stage designs for phase II clinical trials.
R. Simon (1989)
10.1200/JCO.2009.27.7988
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
W. Sun (2010)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1200/JCO.2011.40.6942
The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.
S. Sleijfer (2012)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1158/0008-5472.CAN-05-0808
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
D. Panka (2006)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1200/JCO.2007.15.5242
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
A. Moreno-Aspitia (2009)
10.1200/JCO.2005.02.520
Evaluation of randomized discontinuation design.
B. Freidlin (2005)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.1007/s00280-006-0393-4
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang (2006)
10.1200/JCO.2010.29.3787
Bar the windows but open the door to randomization.
M. Ratain (2010)
10.1158/1078-0432.CCR-07-1355
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
W. Dahut (2008)
10.1200/JCO.2005.05.1359
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
J. Francart (2006)
10.1056/NEJMoa0708857
Sorafenib in advanced hepatocellular carcinoma.
J. Llovet (2008)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma
JM Llovet (2008)
10.1158/0008-5472.CAN-04-1443
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
10.1200/JCO.2009.22.0541
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
G. Blumenschein (2009)
10.1074/JBC.M506551200
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation*
M. Rahmani (2005)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1158/1078-0432.CCR-10-2331
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
R. Kelly (2011)
10.1200/JCO.2008.16.3279
Phase II trial of sorafenib in advanced thyroid cancer.
V. Gupta-Abramson (2008)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomized trial
MF Muers (2008)
10.1158/0008-5472.CAN-06-1377
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Li Liu (2006)
10.1159/000029460
Co-Expression of Vascular Endothelial Growth Factor and Its Receptor flt-1 in Malignant Pleural Mesothelioma
J. Koenig (2000)
10.2174/1381612023393125
Design and discovery of small molecules targeting raf-1 kinase.
T. Lowinger (2002)
10.1038/sj.onc.1208841
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
C. Yu (2005)



This paper is referenced by
10.1007/s13577-019-00286-w
Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance
T. Akahane (2019)
10.3390/cancers10040090
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Y. Sekido (2018)
10.1016/j.jtho.2016.05.020
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing
Marieke Hylebos (2016)
10.1016/j.ctrv.2014.10.007
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
10.3389/fonc.2019.01318
Mesothelioma Driver Genes, Ferroptosis, and Therapy
E. Felley-Bosco (2019)
10.1016/j.jtho.2018.08.2036
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
10.21037/tlcr.2017.06.01
Novel systemic therapy against malignant pleural mesothelioma.
M. R. Mancuso (2017)
10.1042/BST20150252
The role of the HGF/Met axis in mesothelioma.
Thivyan Thayaparan (2016)
10.1177/2373997515600403
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
10.3978/j.issn.2218-6751.2014.07.01
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
10.1016/j.bcp.2016.07.012
New therapeutic strategies for malignant pleural mesothelioma
M. Bonelli (2017)
10.5301/tj.5000436
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1007/s11864-019-0616-7
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
V. Noia (2019)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
10.3389/fonc.2019.01519
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Fabio Nicolini (2019)
10.1158/1535-7163.MCT-16-0229
Genomic Landscape of Malignant Mesotheliomas
S. Kato (2016)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.1038/s41586-019-1426-6
Intercellular interaction dictates cancer cell ferroptosis via Merlin-YAP signalling
J. Wu (2019)
10.1016/j.lungcan.2014.01.021
Surgery for malignant pleural mesothelioma: why, when and what?
L. Lang-Lazdunski (2014)
10.1007/978-3-030-16884-1_16
Targeting Angiogenesis in Malignant Pleural Mesothelioma
A. Scherpereel (2019)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.18632/oncotarget.10428
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
V. Monica (2016)
10.2217/LMT.15.32
New directions in mesothelioma treatment
Anna K. Nowak (2015)
10.2217/fon-2017-0307
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
S. Brosseau (2017)
New Results and Concepts in Systemic Treatment of Mesothelioma
Olga Olevsky (2014)
10.3389/fonc.2020.00126
Antiangiogeneic Strategies in Mesothelioma
A. Nowak (2020)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
Zahlen und Fakten zum Pleuramesotheliom im 21. Jahrhundert: Epidemiologie, Diagnostik, Therapie // Numbers and facts regarding the malignant pleural mesothelioma in the 21st century: epidemiology, diagnostics, therapy
Watzka Sb (2019)
10.1515/pp-2016-0013
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma
Adam Szulkin (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar